The Association between Plasma miRNA-21 Levels with Overall 1-year Survival Rate of Breast Cancer Patients at Various Stages

Authors

  • Pradana Zaky Romadhon 1. Department of Internal Medicine, Airlangga University, Faculty of Medicine, Surabaya, Indonesia 2. Universitas Airlangga Hospital, Surabaya, Indonesia 3. Dr. Soetomo General Teaching Hospital, Surabaya, Indonesia http://orcid.org/0000-0001-9306-5425
  • Ami Ashariati Prayoga 1. Department of Internal Medicine, Airlangga University, Faculty of Medicine, Surabaya, Indonesia 2. Universitas Airlangga Hospital, Surabaya, Indonesia 3. Dr. Soetomo General Teaching Hospital, Surabaya, Indonesia
  • Siprianus Ugroseno Yudho Bintoro 1. Department of Internal Medicine, Airlangga University, Faculty of Medicine, Surabaya, Indonesia 2. Dr. Soetomo General Teaching Hospital, Surabaya, Indonesia
  • Muhammad Noor Diansyah 1. Department of Internal Medicine, Airlangga University, Faculty of Medicine, Surabaya, Indonesia 2. Universitas Airlangga Hospital, Surabaya, Indonesia 3. Dr. Soetomo General Teaching Hospital, Surabaya, Indonesia
  • Putu Niken Amrita 1. Department of Internal Medicine, Airlangga University, Faculty of Medicine, Surabaya, Indonesia 2. Dr. Soetomo General Teaching Hospital, Surabaya, Indonesia
  • Merlyna Savitri 1. Department of Internal Medicine, Airlangga University, Faculty of Medicine, Surabaya, Indonesia 2. Dr. Soetomo General Teaching Hospital, Surabaya, Indonesia
  • Choirina Windradi Universitas Airlangga Hospital, Surabaya, Indonesia

Keywords:

miRNA-21, breast cancer, mortality rate, survival, health

Abstract

Background: miRNA 21 exhibits an increased expression in breast cancer (BC). However, its relationship with the 1-year survival of breast cancer patients is still disputable and under serious discussion. Methods: Cohort prospective study involving 49 breast cancer patients was done, comprising 26 in early stage and 23 in end-stage. We evaluated miRNA-21 values and observed its association with mortality within 1 year. Results: In general, there was a correlation between the increase in miRNA-21 levels and the mortality rate of breast cancer patients (r = 0.651; p <0.05). In the early stages, the increase in miRNA-21 values was not associated with breast cancer mortality (r= 0.25; p=0.218), but in the later stages, we found that the increase in miRNA-21 had a correlation with mortality (r=0.866; p=<0, 05). In advanced stage, high level of miRNA-21 had high asscociation with mortality rate (HR 17,27 95%CI 7,37-40,69). Conclusion: The increase in miRNA-21 values is associated with the 1-year survival of breast cancer patients.

References

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer J Clin. 2018;68(6):394-424.

Kemenkes. Kementrian Kesehatan RI: ‘Situasi Penyakit Kanker Indonesia’2015.

UK. Office of National Statistics: Cancer survival by stage at diagnosis for England 2019. Available from: https://www.gov.uk/government/statistics/cancer-survival-in-england-for-patients-diagnosed-between-2014-and-2018-and-followed-up-until-2019/cancer-survival-in-england-for-patients-diagnosed-between-2014-and-2018-and-followed-up-to-2019.

Uehara M, Kinoshita T, Hojo T, Akashi-Tanaka S, Iwamoto E, Fukutomi T. Long-term prognostic study of carcinoembryonic antigen (CEA) and carbohydrate antigen 15-3 (CA 15-3) in breast cancer. International J Clin Oncol. 2008;13(5):447-51.

Gao J, Zhang Q. Clinical significance of serum miR-21 in breast cancer compared with CA153 and CEA. 2013.

Stieber P, Nagel D, Blankenburg I, et al. Diagnostic efficacy of CA 15-3 and CEA in the early detection of metastatic breast cancer—A retrospective analysis of kinetics on 743 breast cancer patients. Clin Chim Acta. 2015;448:228-31.

Mar-Aguilar F, Mendoza-Ramírez JA, Malagón-Santiago I, et al. Serum circulating microRNA profiling for identification of potential breast cancer biomarkers. Dis Markers. 2013;34(3):163-9.

Zhang J, Jiang C, Shi X, Yu H, Lin H, Peng Y. Diagnostic value of circulating miR-155, miR-21, and miR-10b as promising biomarkers in human breast cancer. Int J Clin Experiment Pathol. 2016;9(10):10258-65.

Kayani M, Kayani MA, Malik FA, Faryal R. Role of miRNAs in breast cancer. Asian Pac J Cancer Prev. 2011;12(12):3175-80.

Yan LX, Huang XF, Shao Q, et al. MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. Rna. 2008;14(11):2348-60.

Wang G, Wang L, Sun S, Wu J, Wang Q. Quantitative Measurement of Serum MicroRNA-21 Expression in Relation to Breast Cancer Metastasis in Chinese Females. Annals Lab Med. 2015;35(2):226-32.

Qian B, Katsaros D, Lu L, et al. High miR-21 expression in breast cancer associated with poor disease-free survival in early stage disease and high TGF-β1. Breast Cancer Res Treat. 2008;117(1):131-40.

Radojicic J, Zaravinos A, Vrekoussis T, Kafousi M, Spandidos DA, Stathopoulos EN. MicroRNA expression analysis in triple-negative (ER, PR and Her2/neu) breast cancer. Cell Cycle. 2011;10(3):507-17.

Aboussekhra A, Al-Khanbashi M, Caramuta S, et al. Tissue and Serum miRNA Profile in Locally Advanced Breast Cancer (LABC) in Response to Neo-Adjuvant Chemotherapy (NAC) Treatment. Plos One. 2016;11(4):e0152032.

Elghoroury EA, ElDine HG, Kamel SA, et al. Evaluation of miRNA-21 and miRNA Let-7 as prognostic markers in patients with breast cancer. Clin Breast Cancer. 2018;18(4):e721-e6.

Cuk K, Zucknick M, Heil J, et al. Circulating microRNAs in plasma as early detection markers for breast cancer. Int J Cancer. 2013;132(7):1602-12.

Shah R. Pathogenesis, prevention, diagnosis and treatment of breast cancer. World J Clin Oncol. 2014;5(3):283.

Sun Y-S, Zhao Z, Yang Z-N, et al. Risk factors and preventions of breast cancer. Int J Biol Sci. 2017;13(11):1387-97.

Lin C-H, Yap YS, Lee K-H, et al. Contrasting epidemiology and clinicopathology of female breast cancer in Asians vs the US population. JNCI: Journal of the National Cancer Institute. 2019;111(12):1298-306.

Dong G, Liang X, Wang D, et al. High expression of miR-21 in triple-negative breast cancers was correlated with a poor prognosis and promoted tumor cell in vitro proliferation. Med Oncol. 2014;31(7).

Fattah H, Mahmoud N, Elzoghby D, Matar M, El Shaer I. Clinical utility of circulating microRNA-21 in breast cancer. Egyptian J Hosp Med. 2018;71(4):2950-5.

Sakr HI, Khowailed AA, Al-Fakharany RS, Abdel-Fattah DS, Taha AA. Serum uric acid level as a predictive biomarker of gestational hypertension severity; A prospective observational case-control study. Reviews on recent clinical trials. 2020;15(3):227-39.

Abdulhussain MM, Hasan NA, Hussain AG. Interrelation of the circulating and tissue MicroRNA-21 with tissue PDCD4 expression and the invasiveness of Iraqi female breast tumors. Indian J Clin Biochem. 2017.

Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proceedings of the National Academy of Sciences. 2008;105(30):10513-8.

Kim Y-K. Extracellular microRNAs as biomarkers in human disease. Chonnam Med J. 2015;51(2):51.

Papadaki C, Stratigos M, Markakis G, et al. Circulating microRNAs in the early prediction of disease recurrence in primary breast cancer. Breast Cancer Res. 2018;20(1).

Downloads

Published

2022-01-10

How to Cite

Romadhon, P. Z., Prayoga, A. A., Bintoro, S. U. Y., Diansyah, M. N., Amrita, P. N., Savitri, M., & Windradi, C. (2022). The Association between Plasma miRNA-21 Levels with Overall 1-year Survival Rate of Breast Cancer Patients at Various Stages. Acta Medica Indonesiana, 53(4), 432. Retrieved from https://actamedindones.org/index.php/ijim/article/view/1886